Neutrophil receptor identified as key culprit in brain injury post-hemorrhage
Researchers have pinpointed neutrophil RAGE as a critical factor in early brain damage following subarachnoid hemorrhage. The molecule promotes inflammation, blood vessel constriction, and reduced brain circulation in the hyperacute phase. Targeting this pathway may offer new therapeutic strategies to improve outcomes after stroke.
In a study published in the Journal of Cerebral Blood Flow & Metabolism in 2026, researchers led by Assistant Professor Hiroshi Ishii and Professor Osamu Hori at Kanazawa University, along with collaborators Yasuhiko Yamamoto and Mitsutoshi Nakada, identified neutrophil RAGE as a pivotal driver of early cerebrovascular injury following subarachnoid hemorrhage (SAH). The findings, based on experiments in wild-type and RAGE-knockout mice, revealed that SAH triggers rapid neurological decline, cerebral vasospasm, and impaired cortical perfusion—phenomena significantly reduced in mice lacking RAGE. Neutrophil accumulation around cerebral arteries was observed within six hours post-hemorrhage, a process strongly suppressed in RAGE-deficient models. The study builds on the team’s 2023 Stroke paper, which first linked immediate sympathetic hyperactivity to alpha1 receptor-mediated vasoconstriction after SAH. This new work extends that timeline by identifying a subsequent inflammatory phase driven by neutrophil RAGE activation via damage-associated molecular patterns (DAMPs) like HMGB1 released from damaged tissue and hematoma. The researchers suggest that targeting this pathway could interrupt the cascade of injury, offering a mechanism-based therapeutic strategy. The exact interaction between the initial sympathetic response and the later neutrophil-mediated inflammation remains unknown, as does whether RAGE inhibition would be safe or effective in humans. Future research aims to m
This discovery could reshape early treatment protocols for subarachnoid hemorrhage, a condition with high mortality and disability rates despite surgical intervention. By identifying neutrophil RAGE as a key upstream mechanism, the research may open avenues for drugs that target inflammation in the hyperacute phase—potentially improving outcomes before vasospasm becomes irreversible. If validated in clinical trials, such therapies could reduce long-term neurological deficits, easing burdens on healthcare systems and caregivers. The pharmaceutical industry may see renewed interest in RAGE inhibitors or anti-inflammatory agents tailored to acute stroke recovery, possibly influencing drug development pipelines. A comparable precedent is the shift from purely mechanical interventions in ischemic stroke to include thrombolytics like tPA, which transformed treatment paradigms. However, unlike that case, this finding remains preclinical; human trials are still pending. The broader impact may